Question
Are monoclonal antibodies against the interleukin-6 receptor effective in patients who are critically ill with COVID-19?
Conclusion
In patients who are critically ill with COVID-19 and require respiratory or cardiovascular organ support, the monocloncal antibodies tocilizumab and sarilumab reduce mortality (number needed to treat [NNT] = 12) and decrease the need for organ support during the 3 weeks following the initiation of therapy. As we have seen with other studies of COVID-19 therapies, benefit is often restricted to specific groups, and this result should not be generalized to less ill patients for whom the benefit has not been demonstrated.
Recent Posts
- No advantage to 325 mg over 81 mg aspirin for persons with established cardiovascular disease (ADAPTABLE)
- How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?
- Are platelet-rich plasma injections effective for alleviating pain and improving function in adults with symptomatic ankle osteoarthritis?
- Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed
- Evidence of benefit is lacking for low back pain relief with muscle relaxants
Leave A Comment